An interventional study of injectable Platelet-Rich Fibrin (i-PRF) and Conventional Gingivectomy in Gingival Overgrowth and Gingival Hyperplasia, sponsored by Şeyma Çardakçı. Completed at 1 site in Turkey (Türkiye). Open to participants aged 15 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Şeyma Çardakçı · Not applicable, Interventional, and Treatment
This study evaluates the clinical and biochemical effects of injectable platelet-rich fibrin (i-PRF) on wound healing after gingivectomy, a surgical procedure used to treat gingival overgrowth. Using a split-mouth design, i-PRF was applied to the surgical site on one side of the mouth (test group), while the other side was treated with conventional gingivectomy alone, without any additional material (control group). Clinical periodontal parameters (plaque index, gingival index, probing depth, clinical attachment level, and bleeding on probing) were assessed at baseline, before surgery, and 28 days after surgery. Additionally, levels of PDGF, IGF-1, and IL-18 in gingival crevicular fluid were measured before surgery and on the third postoperative day to evaluate the biochemical impact of i-PRF on wound healing. A total of 31 participants aged 15-50 years were included in the study.
18 studies on the registry are indexed under Gingival Overgrowth; 1 is open to participants now.
This study's enrollment of 31 is close to the median of 30 across 17 interventional studies indexed under Gingival Overgrowth.
Browse Gingival Overgrowth studies →This is the only study on the registry with Şeyma Çardakçı as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Achieving an optimal level of oral hygiene following Phase I periodontal therapy
Exclusion Criteria:
Patients unable to achieve optimal oral hygiene or with poor compliance/communication
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this split-mouth designed study, the right side of the jaw served as the test site. Following conventional gingivectomy, injectable platelet-rich fibrin (i-PRF) was applied to the surgical wound before placement of the periodontal dressing.
Biological: injectable Platelet-Rich Fibrin (i-PRF) · Procedure: Conventional Gingivectomy
In this split-mouth designed study, the left side of the jaw served as the control site. Conventional gingivectomy was performed and periodontal dressing was placed, without application of any additional material to the wound site.
Procedure: Conventional Gingivectomy
Autologous injectable platelet-rich fibrin, prepared by centrifugation of the patient's own venous blood, applied directly to the gingivectomy wound site.
Also known as: gingivectomy
Standard surgical excision of overgrown gingival tissue using periodontal knives.
Change in Gingival Crevicular Fluid (GCF) IL-18, IGF-1 and PDGF Levels
Time frame: Immediately before surgery (baseline) and postoperative day 3
Plan to share: Yes
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.